Although OMEICOS' synthetic analogs of omega-3 fatty acid epoxides are potentially applicable across a wide range of diseases, our pipeline of exclusively licensed development candidates is currently focused on cardiovascular diseases.
Product candidate atrial fibrillation: OMT-28 is a stable synthetic small molecule analog of the natural omega-3 fatty acid metabolite 17,18-EEQ. Its structure was optimized to provide high efficacy, safety and oral bioavailability. The drug is currently being investigated in preclinical development for the treatment of patients with paroxysmal and persistent atrial fibrillation. The drug has proven its anti-arrhythmic and cardioprotective potential in different in-vivo experimental models.